person · Reporting owner

Struthers Richard Scott

Disclosed activity across 2 companies

Tapewire entity: 17963
SEC CIK: 0001746298

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Frazier Life Sciences Acquisition Corp. IIFLSC · Entity 184069	Director	October 13, 2026	October 13, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Frazier Life Sciences Acquisition Corp. II

Report date October 13, 2026 · Filed October 13, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class B ordinary sharesSEC Table II · derivative / convertible security	Direct	Not disclosed	Reported balance Holding disclosure · report date 2026-10-13 · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · Balance Not disclosed F1: The Class B Ordinary Shares will automatically convert into Class A Ordinary Shares immediately prior to, concurrently with or immediately following the consummation of the Issuer's initial business combination, or at any time prior thereto at the option of the Reporting Person, on a one-for-one basis, subject to adjustment, and have no expiration date.

Filing footnotes · ownership attribution and instrument terms

F1: The Class B Ordinary Shares will automatically convert into Class A Ordinary Shares immediately prior to, concurrently with or immediately following the consummation of the Issuer's initial business combination, or at any time prior thereto at the option of the Reporting Person, on a one-for-one basis, subject to adjustment, and have no expiration date.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Crinetics Pharmaceuticals, Inc.

Report date September 01, 2026 · Filed September 01, 2026

Section 16 reporting ended · disclosed 2026-09-01. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Ending reported balance After 2026-09-01 transaction · row 12 2 source rows · reconciled sequence Row 1 · 2026-09-01 · Disposition to issuer · Disposed 248,043 · Balance 176,663 F1: Pursuant to the Agreement and Plan of Merger, dated as of July 6, 2026 (the "Merger Agreement"), by and among Crinetics Pharmaceuticals, Inc., a Delaware corporation (the "Company"), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation ("Parent"), and Clark Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of September 1, 2026 (the "Effective Time"). At the Effective Time, each share of common stock of the Company, par value $0.001 per share (the "Company Common Stock"), issued and outstanding immediately prior to the Effective Time, except as provided in the Merger Agreement, was canceled and automatically converted into the right to receive $85.00 per share in cash, without interest and subject to any applicable tax withholdings (the "Merger Consideration"). Row 12 · 2026-09-01 · Disposition to issuer · Disposed 176,663 · Balance 0 F2: The transaction reported on this line reflects the cancellation in the Merger of restricted stock units of the Company (each, a "Company RSU"), each of which represented a contingent right to receive one share of the Issuer's Common Stock. Immediately prior to the Effective Time, each Company RSU that was then outstanding but not vested became immediately vested in full. At the Effective Time, each outstanding Company RSU was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration, less any applicable tax withholding.
Common StockSEC Table I · non-derivative	IndirectBy Spouse	Reported balance After 2026-09-01 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2026-09-01 · Disposition to issuer · Disposed 1,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of July 6, 2026 (the "Merger Agreement"), by and among Crinetics Pharmaceuticals, Inc., a Delaware corporation (the "Company"), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation ("Parent"), and Clark Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of September 1, 2026 (the "Effective Time"). At the Effective Time, each share of common stock of the Company, par value $0.001 per share (the "Company Common Stock"), issued and outstanding immediately prior to the Effective Time, except as provided in the Merger Agreement, was canceled and automatically converted into the right to receive $85.00 per share in cash, without interest and subject to any applicable tax withholdings (the "Merger Consideration").
Common StockSEC Table I · non-derivative	IndirectBy Family Trust 1	Reported balance After 2026-09-01 transaction · row 3 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 3 · 2026-09-01 · Disposition to issuer · Disposed 136,805 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of July 6, 2026 (the "Merger Agreement"), by and among Crinetics Pharmaceuticals, Inc., a Delaware corporation (the "Company"), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation ("Parent"), and Clark Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of September 1, 2026 (the "Effective Time"). At the Effective Time, each share of common stock of the Company, par value $0.001 per share (the "Company Common Stock"), issued and outstanding immediately prior to the Effective Time, except as provided in the Merger Agreement, was canceled and automatically converted into the right to receive $85.00 per share in cash, without interest and subject to any applicable tax withholdings (the "Merger Consideration").
Common StockSEC Table I · non-derivative	IndirectBy Family Trust 2	Reported balance After 2026-09-01 transaction · row 4 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 4 · 2026-09-01 · Disposition to issuer · Disposed 106,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of July 6, 2026 (the "Merger Agreement"), by and among Crinetics Pharmaceuticals, Inc., a Delaware corporation (the "Company"), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation ("Parent"), and Clark Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of September 1, 2026 (the "Effective Time"). At the Effective Time, each share of common stock of the Company, par value $0.001 per share (the "Company Common Stock"), issued and outstanding immediately prior to the Effective Time, except as provided in the Merger Agreement, was canceled and automatically converted into the right to receive $85.00 per share in cash, without interest and subject to any applicable tax withholdings (the "Merger Consideration").
Common StockSEC Table I · non-derivative	IndirectBy Family Trust 3	Reported balance After 2026-09-01 transaction · row 5 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 5 · 2026-09-01 · Disposition to issuer · Disposed 110,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of July 6, 2026 (the "Merger Agreement"), by and among Crinetics Pharmaceuticals, Inc., a Delaware corporation (the "Company"), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation ("Parent"), and Clark Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of September 1, 2026 (the "Effective Time"). At the Effective Time, each share of common stock of the Company, par value $0.001 per share (the "Company Common Stock"), issued and outstanding immediately prior to the Effective Time, except as provided in the Merger Agreement, was canceled and automatically converted into the right to receive $85.00 per share in cash, without interest and subject to any applicable tax withholdings (the "Merger Consideration").
Common StockSEC Table I · non-derivative	IndirectBy Family Trust 4	Reported balance After 2026-09-01 transaction · row 6 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 6 · 2026-09-01 · Disposition to issuer · Disposed 100,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of July 6, 2026 (the "Merger Agreement"), by and among Crinetics Pharmaceuticals, Inc., a Delaware corporation (the "Company"), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation ("Parent"), and Clark Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of September 1, 2026 (the "Effective Time"). At the Effective Time, each share of common stock of the Company, par value $0.001 per share (the "Company Common Stock"), issued and outstanding immediately prior to the Effective Time, except as provided in the Merger Agreement, was canceled and automatically converted into the right to receive $85.00 per share in cash, without interest and subject to any applicable tax withholdings (the "Merger Consideration").
Common StockSEC Table I · non-derivative	IndirectBy Family Trust 5	Reported balance After 2026-09-01 transaction · row 7 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 7 · 2026-09-01 · Disposition to issuer · Disposed 111,100 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of July 6, 2026 (the "Merger Agreement"), by and among Crinetics Pharmaceuticals, Inc., a Delaware corporation (the "Company"), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation ("Parent"), and Clark Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of September 1, 2026 (the "Effective Time"). At the Effective Time, each share of common stock of the Company, par value $0.001 per share (the "Company Common Stock"), issued and outstanding immediately prior to the Effective Time, except as provided in the Merger Agreement, was canceled and automatically converted into the right to receive $85.00 per share in cash, without interest and subject to any applicable tax withholdings (the "Merger Consideration").
Common StockSEC Table I · non-derivative	IndirectBy Family Trust 6	Reported balance After 2026-09-01 transaction · row 8 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 8 · 2026-09-01 · Disposition to issuer · Disposed 111,100 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of July 6, 2026 (the "Merger Agreement"), by and among Crinetics Pharmaceuticals, Inc., a Delaware corporation (the "Company"), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation ("Parent"), and Clark Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of September 1, 2026 (the "Effective Time"). At the Effective Time, each share of common stock of the Company, par value $0.001 per share (the "Company Common Stock"), issued and outstanding immediately prior to the Effective Time, except as provided in the Merger Agreement, was canceled and automatically converted into the right to receive $85.00 per share in cash, without interest and subject to any applicable tax withholdings (the "Merger Consideration").
Common StockSEC Table I · non-derivative	IndirectBy Family Trust 7	Reported balance After 2026-09-01 transaction · row 9 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 9 · 2026-09-01 · Disposition to issuer · Disposed 111,100 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of July 6, 2026 (the "Merger Agreement"), by and among Crinetics Pharmaceuticals, Inc., a Delaware corporation (the "Company"), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation ("Parent"), and Clark Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of September 1, 2026 (the "Effective Time"). At the Effective Time, each share of common stock of the Company, par value $0.001 per share (the "Company Common Stock"), issued and outstanding immediately prior to the Effective Time, except as provided in the Merger Agreement, was canceled and automatically converted into the right to receive $85.00 per share in cash, without interest and subject to any applicable tax withholdings (the "Merger Consideration").
Common StockSEC Table I · non-derivative	IndirectBy Family Trust 8	Reported balance After 2026-09-01 transaction · row 10 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 10 · 2026-09-01 · Disposition to issuer · Disposed 111,100 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of July 6, 2026 (the "Merger Agreement"), by and among Crinetics Pharmaceuticals, Inc., a Delaware corporation (the "Company"), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation ("Parent"), and Clark Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of September 1, 2026 (the "Effective Time"). At the Effective Time, each share of common stock of the Company, par value $0.001 per share (the "Company Common Stock"), issued and outstanding immediately prior to the Effective Time, except as provided in the Merger Agreement, was canceled and automatically converted into the right to receive $85.00 per share in cash, without interest and subject to any applicable tax withholdings (the "Merger Consideration").
Common StockSEC Table I · non-derivative	IndirectBy Charitable Trust	Reported balance After 2026-09-01 transaction · row 11 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 11 · 2026-09-01 · Disposition to issuer · Disposed 80,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of July 6, 2026 (the "Merger Agreement"), by and among Crinetics Pharmaceuticals, Inc., a Delaware corporation (the "Company"), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation ("Parent"), and Clark Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of September 1, 2026 (the "Effective Time"). At the Effective Time, each share of common stock of the Company, par value $0.001 per share (the "Company Common Stock"), issued and outstanding immediately prior to the Effective Time, except as provided in the Merger Agreement, was canceled and automatically converted into the right to receive $85.00 per share in cash, without interest and subject to any applicable tax withholdings (the "Merger Consideration").
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.19 · Expires 2029-03-08	Direct	Reported balance After 2026-09-01 transaction · row 13 Instrument identity requires review; Table II rows are not merged. 1 source row Row 13 · 2026-09-01 · Disposition to issuer · Disposed 172,281 · Balance 0 F3: The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration. F4: The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.61 · Expires 2030-02-24	Direct	Reported balance After 2026-09-01 transaction · row 14 Instrument identity requires review; Table II rows are not merged. 1 source row Row 14 · 2026-09-01 · Disposition to issuer · Disposed 195,578 · Balance 0 F3: The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration. F4: The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.29 · Expires 2031-02-26	Direct	Reported balance After 2026-09-01 transaction · row 15 Instrument identity requires review; Table II rows are not merged. 1 source row Row 15 · 2026-09-01 · Disposition to issuer · Disposed 259,058 · Balance 0 F3: The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration. F4: The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.02 · Expires 2032-02-29	Direct	Reported balance After 2026-09-01 transaction · row 16 Instrument identity requires review; Table II rows are not merged. 1 source row Row 16 · 2026-09-01 · Disposition to issuer · Disposed 244,205 · Balance 0 F3: The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration. F4: The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.64 · Expires 2033-02-28	Direct	Reported balance After 2026-09-01 transaction · row 17 Instrument identity requires review; Table II rows are not merged. 1 source row Row 17 · 2026-09-01 · Disposition to issuer · Disposed 287,700 · Balance 0 F3: The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration. F4: The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $43.51 · Expires 2034-03-03	Direct	Reported balance After 2026-09-01 transaction · row 18 Instrument identity requires review; Table II rows are not merged. 1 source row Row 18 · 2026-09-01 · Disposition to issuer · Disposed 240,000 · Balance 0 F3: The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration. F4: The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $36.86 · Expires 2035-02-19	Direct	Reported balance After 2026-09-01 transaction · row 19 Instrument identity requires review; Table II rows are not merged. 1 source row Row 19 · 2026-09-01 · Disposition to issuer · Disposed 313,000 · Balance 0 F3: The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration. F4: The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $43.79 · Expires 2036-02-23	Direct	Reported balance After 2026-09-01 transaction · row 20 Instrument identity requires review; Table II rows are not merged. 1 source row Row 20 · 2026-09-01 · Disposition to issuer · Disposed 228,000 · Balance 0 F3: The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration. F4: The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Agreement and Plan of Merger, dated as of July 6, 2026 (the "Merger Agreement"), by and among Crinetics Pharmaceuticals, Inc., a Delaware corporation (the "Company"), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation ("Parent"), and Clark Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of September 1, 2026 (the "Effective Time"). At the Effective Time, each share of common stock of the Company, par value $0.001 per share (the "Company Common Stock"), issued and outstanding immediately prior to the Effective Time, except as provided in the Merger Agreement, was canceled and automatically converted into the right to receive $85.00 per share in cash, without interest and subject to any applicable tax withholdings (the "Merger Consideration").

F2: The transaction reported on this line reflects the cancellation in the Merger of restricted stock units of the Company (each, a "Company RSU"), each of which represented a contingent right to receive one share of the Issuer's Common Stock. Immediately prior to the Effective Time, each Company RSU that was then outstanding but not vested became immediately vested in full. At the Effective Time, each outstanding Company RSU was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration, less any applicable tax withholding.

F3: The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration.

F4: The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
September 26, 2025 Filed Sep 30, 2025 20:42 UTC	Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579	SaleCommon Stock	4,000	$45.00	$180,000.00	Disclosure SEC source: 0001658247-25-000011 · wk-form4_1759264973.xml · nonDerivative · entry 1 Struthers Richard Scott · CIK 0001746298 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Indirect · By Family Trust 2 Disclosed balance after: 106,000 F1 · kind: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 30, 2024. F2 · price: The common stock was sold by the Reporting Person in open market transactions on the transaction date, with a sale price of $45.00 per share. Read SEC document
May 14, 2025 Filed May 16, 2025 20:30 UTC	Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579	GiftCommon Stock	90,400	$0.00	$0.00	Disclosure SEC source: 0000950170-25-073605 · ownership.xml · nonDerivative · entry 2 Struthers Richard Scott · CIK 0001746298 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By Family Trust 1 Disclosed balance after: 661,205 F1 · kind: Bona fide gift made by the Reporting person for no consideration. Read SEC document
May 14, 2025 Filed May 16, 2025 20:30 UTC	Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579	GiftCommon Stock	90,400	$0.00	$0.00	Disclosure SEC source: 0000950170-25-073605 · ownership.xml · nonDerivative · entry 1 Struthers Richard Scott · CIK 0001746298 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 320,017 F1 · kind: Bona fide gift made by the Reporting person for no consideration. Read SEC document
April 02, 2025 Filed Apr 4, 2025 20:30 UTC	Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579	Exercise / conversionStock Option (Right to Buy) · Derivative	81,270	$0.00 Strike: $1.91	$0.00	Disclosure SEC source: 0000950170-25-051170 · ownership.xml · derivative · entry 7 Struthers Richard Scott · CIK 0001746298 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 81,270 shares Expires 2028-03-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 1/48th of the shares subject to the option vested on April 16, 2018, and 1/48th of the shares subject to the option vest monthly thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document
April 02, 2025 Filed Apr 4, 2025 20:30 UTC	Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579	Exercise / conversionCommon Stock	81,270	$1.91	$155,225.70	Disclosure SEC source: 0000950170-25-051170 · ownership.xml · nonDerivative · entry 1 Struthers Richard Scott · CIK 0001746298 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 410,417 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
March 19, 2025 Filed Mar 21, 2025 22:31 UTC	Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579	SaleCommon Stock	875	$34.83	$30,476.25	Disclosure SEC source: 0000950170-25-043401 · ownership.xml · nonDerivative · entry 2 Struthers Richard Scott · CIK 0001746298 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 329,147 F3 · kind: Represents the number of shares of common stock sold by the Issuer to cover the Reporting Person's tax withholding obligation upon the vesting of Restricted Stock Units granted on February 28, 2022, March 1, 2023, and March 4, 2024. The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person. F4 · price: The common stock was sold in open market transactions on the transaction date, with a volume weighted average sales price of $34.83 per share. The range of sales prices on the transaction date was $34.78 to $35.00 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request. Read SEC document
March 19, 2025 Filed Mar 21, 2025 22:31 UTC	Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579	SaleCommon Stock	16,463	$34.17	$562,540.71	Disclosure SEC source: 0000950170-25-043401 · ownership.xml · nonDerivative · entry 1 Struthers Richard Scott · CIK 0001746298 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 330,022 F1 · kind: Represents the number of shares of common stock sold by the Issuer to cover the Reporting Person's tax withholding obligation upon the vesting of Restricted Stock Units granted on February 28, 2022, March 1, 2023, and March 4, 2024. The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The common stock was sold in open market transactions on the transaction date, with a volume weighted average sales price of $34.17 per share. The range of sales prices on the transaction date was $33.78 to $34.77 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request. Read SEC document
February 20, 2025 Filed Feb 24, 2025 21:30 UTC	Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579	GrantStock Option (Right to Buy) · Derivative	313,000	$0.00 Strike: $36.86	$0.00	Disclosure SEC source: 0000950170-25-025667 · ownership.xml · derivative · entry 7 Struthers Richard Scott · CIK 0001746298 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 313,000 Underlying: Common Stock · 313,000 shares Expires 2035-02-19 F2 · derivative.exercise_date: The stock option shall vest and become exercisable in a series of forty-eight (48) successive equal monthly installments measured from the vesting commencement date of February 20, 2025. Read SEC document
February 20, 2025 Filed Feb 24, 2025 21:30 UTC	Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579	GrantCommon Stock	89,000	$0.00	$0.00	Disclosure SEC source: 0000950170-25-025667 · ownership.xml · nonDerivative · entry 1 Struthers Richard Scott · CIK 0001746298 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 346,485 F1 · price: The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 25% vesting annually beginning on March 15, 2026. Read SEC document
December 02, 2024 Filed Dec 4, 2024 21:30 UTC	Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579	SaleCommon Stock	10,000	$57.57	$575,700.00	Disclosure SEC source: 0000950170-24-133297 · ownership.xml · nonDerivative · entry 1 Struthers Richard Scott · CIK 0001746298 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Indirect · By Family Trust 4 Disclosed balance after: 100,000 F1 · kind: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The common stock was sold by the reporting person in open market transactions on the transaction date, with a weighted average sales price of $57.57 per share. The range of sales prices on the transaction date was $56.90 to $58.07 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request. Read SEC document
May 08, 2024 Filed May 10, 2024 20:57 UTC	Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579	Exercise / conversionStock Option (Right to Buy) · Derivative	107,448	$0.00 Strike: $9.28	$0.00	Disclosure SEC source: 0000950170-24-057926 · ownership.xml · derivative · entry 8 Struthers Richard Scott · CIK 0001746298 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,342 Underlying: Common Stock · 107,448 shares Expires 2028-05-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 1/48th of the shares subject to the option vested on June 25, 2018, and 1/48th of the shares subject to the option vested monthly thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document
May 08, 2024 Filed May 10, 2024 20:57 UTC	Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579	SaleCommon Stock	107,448	$49.40	$5,307,931.20	Disclosure SEC source: 0000950170-24-057926 · ownership.xml · nonDerivative · entry 2 Struthers Richard Scott · CIK 0001746298 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 257,485 F1 · kind: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan entered into in March 2023. F2 · price: The common stock was sold by the reporting person in open market transactions on the transaction date, with a weighted average sales price of $49.40 per share. The range of sales prices on the transaction date was $48.95 to $50.15 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request. Read SEC document
May 08, 2024 Filed May 10, 2024 20:57 UTC	Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579	Exercise / conversionCommon Stock	107,448	$9.28	$997,117.44	Disclosure SEC source: 0000950170-24-057926 · ownership.xml · nonDerivative · entry 1 Struthers Richard Scott · CIK 0001746298 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 364,933 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
April 18, 2024 Filed Apr 22, 2024 21:23 UTC	Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579	GiftCommon Stock	350	$0.00	$0.00	Disclosure SEC source: 0000950170-24-046523 · ownership.xml · nonDerivative · entry 1 Struthers Richard Scott · CIK 0001746298 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 257,485 F1 · kind: Bona fide gift made by the Reporting Person for no consideration. Read SEC document
April 15, 2024 Filed Apr 17, 2024 20:30 UTC	Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579	Exercise / conversionStock Option (Right to Buy) · Derivative	20,000	$0.00 Strike: $1.91	$0.00	Disclosure SEC source: 0000950170-24-045136 · ownership.xml · derivative · entry 7 Struthers Richard Scott · CIK 0001746298 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,270 Underlying: Common Stock · 20,000 shares Expires 2028-03-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 1/48th of the shares subject to the option vested on April 16, 2018, and 1/48th of the shares subject to the option vest monthly thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document
April 15, 2024 Filed Apr 17, 2024 20:30 UTC	Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579	Exercise / conversionCommon Stock	20,000	$1.91	$38,200.00	Disclosure SEC source: 0000950170-24-045136 · ownership.xml · nonDerivative · entry 1 Struthers Richard Scott · CIK 0001746298 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 257,835 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
April 04, 2024 Filed Apr 8, 2024 21:09 UTC	Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579	Exercise / conversionNon-qualified stock option (Right to Buy) · Derivative	40,951	$0.00 Strike: $9.28	$0.00	Disclosure SEC source: 0000950170-24-042681 · ownership.xml · derivative · entry 8 Struthers Richard Scott · CIK 0001746298 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 123,790 Underlying: Common Stock · 40,951 shares Expires 2028-05-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 1/48th of the shares subject to the option vested on June 25, 2018, and 1/48th of the shares subject to the option vested monthly thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document
April 04, 2024 Filed Apr 8, 2024 21:09 UTC	Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579	SaleCommon Stock	40,951	$49.17	$2,013,560.67	Disclosure SEC source: 0000950170-24-042681 · ownership.xml · nonDerivative · entry 2 Struthers Richard Scott · CIK 0001746298 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 237,835 F1 · kind: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan. F2 · price: The common stock was sold by the reporting person in open market transactions on the transaction date, with a weighted average sales price of $49.17 per share. The range of sales prices on the transaction date was $48.95 to $49.56 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request. Read SEC document
April 04, 2024 Filed Apr 8, 2024 21:09 UTC	Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579	Exercise / conversionCommon Stock	40,951	$9.28	$380,025.28	Disclosure SEC source: 0000950170-24-042681 · ownership.xml · nonDerivative · entry 1 Struthers Richard Scott · CIK 0001746298 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 278,786 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
March 18, 2024 Filed Mar 20, 2024 22:31 UTC	Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579	Tax withholdingCommon Stock	12,687	$38.14	$483,882.18	Disclosure SEC source: 0001209191-24-005008 · doc4.xml · nonDerivative · entry 1 Struthers Richard Scott · CIK 0001746298 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 237,835 F1 · kind: Represents the number of shares of common stock withheld by the Issuer to cover the reporting person's tax withholding obligation upon the vesting of Restricted Stock Units granted on February 28, 2022 and March 1, 2023. The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document
March 04, 2024 Filed Mar 7, 2024 01:01 UTC	Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579	GrantStock Option (right to buy) · Derivative	240,000	$0.00 Strike: $43.51	$0.00	Disclosure SEC source: 0001209191-24-004608 · doc4.xml · derivative · entry 7 Struthers Richard Scott · CIK 0001746298 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 240,000 Underlying: Common Stock · 240,000 shares Expires 2034-03-03 F2 · derivative.exercise_date: The stock option shall vest and become exercisable in a series of forty-eight (48) successive equal monthly installments measured from the vesting commencement date of March 4, 2024. Read SEC document
March 04, 2024 Filed Mar 7, 2024 01:01 UTC	Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579	GrantCommon Stock	65,000	$0.00	$0.00	Disclosure SEC source: 0001209191-24-004608 · doc4.xml · nonDerivative · entry 1 Struthers Richard Scott · CIK 0001746298 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 250,522 F1 · price: The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 25% vesting annually beginning on March 15, 2025. Read SEC document
February 12, 2024 Filed Feb 14, 2024 21:28 UTC	Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579	GiftCommon Stock	20,000	$0.00	$0.00	Disclosure SEC source: 0001209191-24-003354 · doc4.xml · nonDerivative · entry 4 Struthers Richard Scott · CIK 0001746298 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By Family Trust 4 Disclosed balance after: 110,000 F1 · kind: Bona fide gift made by the Reporting Person for no consideration. Read SEC document
February 12, 2024 Filed Feb 14, 2024 21:28 UTC	Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579	GiftCommon Stock	20,000	$0.00	$0.00	Disclosure SEC source: 0001209191-24-003354 · doc4.xml · nonDerivative · entry 3 Struthers Richard Scott · CIK 0001746298 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By Family Trust 3 Disclosed balance after: 110,000 F1 · kind: Bona fide gift made by the Reporting Person for no consideration. Read SEC document
February 12, 2024 Filed Feb 14, 2024 21:28 UTC	Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579	GiftCommon Stock	20,000	$0.00	$0.00	Disclosure SEC source: 0001209191-24-003354 · doc4.xml · nonDerivative · entry 2 Struthers Richard Scott · CIK 0001746298 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By Family Trust 2 Disclosed balance after: 110,000 F1 · kind: Bona fide gift made by the Reporting Person for no consideration. Read SEC document
February 12, 2024 Filed Feb 14, 2024 21:28 UTC	Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579	GiftCommon Stock	60,000	$0.00	$0.00	Disclosure SEC source: 0001209191-24-003354 · doc4.xml · nonDerivative · entry 1 Struthers Richard Scott · CIK 0001746298 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By Family Trust 1 Disclosed balance after: 570,805 F1 · kind: Bona fide gift made by the Reporting Person for no consideration. Read SEC document
November 09, 2023 Filed Nov 13, 2023 21:33 UTC	Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579	Exercise / conversionIncentive stock option (Right to Buy) · Derivative	50,000	$0.00 Strike: $1.91	$0.00	Disclosure SEC source: 0001209191-23-055022 · doc4.xml · derivative · entry 7 Struthers Richard Scott · CIK 0001746298 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 101,270 Underlying: Common Stock · 50,000 shares Expires 2028-03-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 1/48th of the shares subject to the option vested on April 16, 2018, and 1/48th of the shares subject to the option vested monthly thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document
November 09, 2023 Filed Nov 13, 2023 21:33 UTC	Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579	Exercise / conversionCommon Stock	50,000	$1.91	$95,500.00	Disclosure SEC source: 0001209191-23-055022 · doc4.xml · nonDerivative · entry 1 Struthers Richard Scott · CIK 0001746298 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 185,522 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
November 03, 2023 Filed Nov 6, 2023 23:02 UTC	Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579	Exercise / conversionNon-qualified stock option (Right to Buy) · Derivative	199,082	$0.00 Strike: $9.28	$0.00	Disclosure SEC source: 0001209191-23-054567 · doc4.xml · derivative · entry 11 Struthers Richard Scott · CIK 0001746298 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 164,741 Underlying: Common Stock · 199,082 shares Expires 2028-05-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 1/48th of the shares subject to the option vested on June 25, 2018, and 1/48th of the shares subject to the option vested monthly thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document
November 03, 2023 Filed Nov 6, 2023 23:02 UTC	Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579	SaleCommon Stock	199,082	$30.56	$6,083,945.92	Disclosure SEC source: 0001209191-23-054567 · doc4.xml · nonDerivative · entry 4 Struthers Richard Scott · CIK 0001746298 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 135,522 F1 · price: The common stock was sold by the reporting person in open market transactions on the transaction date, with a weighted average sales price of $30.56 per share. The range of sales prices on the transaction date was $29.95 to $31.37 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request. Read SEC document
November 03, 2023 Filed Nov 6, 2023 23:02 UTC	Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579	Exercise / conversionCommon Stock	199,082	$9.28	$1,847,480.96	Disclosure SEC source: 0001209191-23-054567 · doc4.xml · nonDerivative · entry 3 Struthers Richard Scott · CIK 0001746298 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 334,604 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
November 02, 2023 Filed Nov 6, 2023 23:02 UTC	Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579	Exercise / conversionNon-qualified stock option (Right to Buy) · Derivative	918	$0.00 Strike: $9.28	$0.00	Disclosure SEC source: 0001209191-23-054567 · doc4.xml · derivative · entry 10 Struthers Richard Scott · CIK 0001746298 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 363,823 Underlying: Common Stock · 918 shares Expires 2028-05-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 1/48th of the shares subject to the option vested on June 25, 2018, and 1/48th of the shares subject to the option vested monthly thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document
November 02, 2023 Filed Nov 6, 2023 23:02 UTC	Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579	SaleCommon Stock	918	$29.95	$27,494.10	Disclosure SEC source: 0001209191-23-054567 · doc4.xml · nonDerivative · entry 2 Struthers Richard Scott · CIK 0001746298 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 135,522 Read SEC document
November 02, 2023 Filed Nov 6, 2023 23:02 UTC	Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579	Exercise / conversionCommon Stock	918	$9.28	$8,519.04	Disclosure SEC source: 0001209191-23-054567 · doc4.xml · nonDerivative · entry 1 Struthers Richard Scott · CIK 0001746298 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 136,440 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
August 14, 2023 Filed Aug 16, 2023 20:30 UTC	Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579	Exercise / conversionIncentve stock option (Right to Buy) · Derivative	10,000	$0.00 Strike: $1.91	$0.00	Disclosure SEC source: 0001209191-23-046024 · doc4.xml · derivative · entry 7 Struthers Richard Scott · CIK 0001746298 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 151,270 Underlying: Common Stock · 10,000 shares Expires 2028-03-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 1/48th of the shares subject to the option vested on April 16, 2018, and 1/48th of the shares subject to the option vested monthly thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document
August 14, 2023 Filed Aug 16, 2023 20:30 UTC	Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579	Exercise / conversionCommon Stock	10,000	$1.91	$19,100.00	Disclosure SEC source: 0001209191-23-046024 · doc4.xml · nonDerivative · entry 1 Struthers Richard Scott · CIK 0001746298 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 135,522 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
July 13, 2023 Filed Jul 13, 2023 20:56 UTC	Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579	SaleCommon Stock	14,157	$20.35	$288,094.95	Disclosure SEC source: 0001209191-23-042229 · doc4.xml · nonDerivative · entry 3 Struthers Richard Scott · CIK 0001746298 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Indirect · By Family Trust 1 Disclosed balance after: 630,805 F3 · price: The common stock was sold by the reporting person in open market transactions on the transaction date, with a weighted average sales price of $20.35 per share. The range of sales prices on the transaction date was $20.10 to $20.68 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request. Read SEC document
July 12, 2023 Filed Jul 13, 2023 20:56 UTC	Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579	SaleCommon Stock	11,459	$20.17	$231,128.03	Disclosure SEC source: 0001209191-23-042229 · doc4.xml · nonDerivative · entry 2 Struthers Richard Scott · CIK 0001746298 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Indirect · By Family Trust 1 Disclosed balance after: 644,962 F2 · price: The common stock was sold by the reporting person in open market transactions on the transaction date, with a weighted average sales price of $20.17 per share. The range of sales prices on the transaction date was $20.10 to $20.31 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request. Read SEC document
July 11, 2023 Filed Jul 13, 2023 20:56 UTC	Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579	SaleCommon Stock	24,384	$20.14	$491,093.76	Disclosure SEC source: 0001209191-23-042229 · doc4.xml · nonDerivative · entry 1 Struthers Richard Scott · CIK 0001746298 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Indirect · By Family Trust 1 Disclosed balance after: 656,421 F1 · price: The common stock was sold by the reporting person in open market transactions on the transaction date, with a weighted average sales price of $20.14 per share. The range of sales prices on the transaction date was $20.10 to $20.25 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request Read SEC document
June 16, 2023 Filed Jun 21, 2023 21:27 UTC	Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579	SaleCommon Stock	50,000	$20.81	$1,040,500.00	Disclosure SEC source: 0001209191-23-038851 · doc4.xml · nonDerivative · entry 1 Struthers Richard Scott · CIK 0001746298 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Indirect · By Family Trust 1 Disclosed balance after: 680,805 Read SEC document
March 16, 2023 Filed Mar 17, 2023 21:10 UTC	Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579	Tax withholdingCommon Stock	4,628	$17.12	$79,231.36	Disclosure SEC source: 0001209191-23-019772 · doc4.xml · nonDerivative · entry 1 Struthers Richard Scott · CIK 0001746298 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,522 F1 · kind: Represents the number of shares of common stock withheld by the Issuer to cover the reporting person's tax withholding obligation upon the vesting of Restricted Stock Units granted on February 28, 2022. The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document
March 01, 2023 Filed Mar 3, 2023 21:31 UTC	Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579	GrantCommon Stock (right to buy) · Derivative	287,700	$0.00 Strike: $19.64	$0.00	Disclosure SEC source: 0001209191-23-015524 · doc4.xml · derivative · entry 7 Struthers Richard Scott · CIK 0001746298 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 287,700 Underlying: Common Stock · 287,700 shares Expires 2033-02-28 F2 · derivative.exercise_date: The stock option shall vest and become exercisable in a series of forty-eight (48) successive equal monthly installments measured from the vesting commencement date of March 1, 2023. Read SEC document
March 01, 2023 Filed Mar 3, 2023 21:31 UTC	Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579	GrantCommon Stock	61,650	$0.00	$0.00	Disclosure SEC source: 0001209191-23-015524 · doc4.xml · nonDerivative · entry 1 Struthers Richard Scott · CIK 0001746298 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,150 F1 · price: The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 25% vesting annually beginning on March 15, 2024. Read SEC document
October 12, 2022 Filed Oct 14, 2022 20:55 UTC	Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579	Exercise / conversionIncentive stock option (Right to Buy) · Derivative	11,100	$0.00 Strike: $1.91	$0.00	Disclosure SEC source: 0001209191-22-053680 · doc4.xml · derivative · entry 7 Struthers Richard Scott · CIK 0001746298 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,270 Underlying: Common Stock · 11,100 shares Expires 2028-03-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 1/48th of the shares subject to the option vested on April 16, 2018, and 1/48th of the shares subject to the option vested monthly thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document
October 12, 2022 Filed Oct 14, 2022 20:55 UTC	Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579	Exercise / conversionCommon Stock	11,100	$1.91	$21,201.00	Disclosure SEC source: 0001209191-22-053680 · doc4.xml · nonDerivative · entry 1 Struthers Richard Scott · CIK 0001746298 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
April 13, 2022 Filed Apr 15, 2022 22:00 UTC	Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579	SaleCommon Stock	69,176	$27.53	$1,904,256.18	Disclosure SEC source: 0001209191-22-024531 · doc4.xml · nonDerivative · entry 3 Struthers Richard Scott · CIK 0001746298 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Trust 1 Disclosed balance after: 730,805 F1 · kind: The sales reported in this Form 4 were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date. F4 · price: The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $27.5277 per share. The range of actual sales prices on the transaction date was $27.02 to $27.845 per share. Detailed information on the exact number of shares sold at each price can be obtained from the issuer upon request. Read SEC document
April 13, 2022 Filed Apr 15, 2022 22:00 UTC	Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579	SaleCommon Stock	44,793	$26.52	$1,188,040.26	Disclosure SEC source: 0001209191-22-024531 · doc4.xml · nonDerivative · entry 2 Struthers Richard Scott · CIK 0001746298 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Trust 1 Disclosed balance after: 799,981 F1 · kind: The sales reported in this Form 4 were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date. F3 · price: The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $26.5229 per share. The range of actual sales prices on the transaction date was $26.02 to $27.005 per share. Detailed information on the exact number of shares sold at each price can be obtained from the issuer upon request. Read SEC document
April 13, 2022 Filed Apr 15, 2022 22:00 UTC	Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579	SaleCommon Stock	24,674	$25.42	$627,329.05	Disclosure SEC source: 0001209191-22-024531 · doc4.xml · nonDerivative · entry 1 Struthers Richard Scott · CIK 0001746298 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Trust 1 Disclosed balance after: 844,774 F1 · kind: The sales reported in this Form 4 were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date. F2 · price: The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $25.4247 per share. The range of actual sales prices on the transaction date was $25.00 to $25.98 per share. Detailed information on the exact number of shares sold at each price can be obtained from the issuer upon request. Read SEC document
April 05, 2022 Filed Apr 7, 2022 21:58 UTC	Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579	SaleCommon Stock	21,357	$25.34	$541,224.82	Disclosure SEC source: 0001209191-22-023722 · doc4.xml · nonDerivative · entry 1 Struthers Richard Scott · CIK 0001746298 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Trust 1 Disclosed balance after: 869,448 F1 · kind: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date. F2 · price: The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $25.3418 per share. The range of actual sales prices on the transaction date was $25.00 to $25.57 per share. Detailed information on the exact number of shares sold at each price can be obtained from the issuer upon request. Read SEC document
February 28, 2022 Filed Mar 3, 2022 02:00 UTC	Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579	GrantCommon Stock (right to buy) · Derivative	249,200	$0.00 Strike: $20.02	$0.00	Disclosure SEC source: 0001209191-22-015134 · doc4.xml · derivative · entry 7 Struthers Richard Scott · CIK 0001746298 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 249,200 Underlying: Common Stock · 249,200 shares Expires 2032-02-27 F2 · derivative.exercise_date: The stock option shall vest and become exercisable in a series of forty-eight (48) successive equal monthly installments measured from the vesting commencement date of February 28, 2022. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.